Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cadonilimab by Akeso for Metastatic Biliary Tract Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
Cadonilimab by Akeso for Signet Ring Cell Squamous Cell Carcinoma: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Signet Ring Cell Squamous Cell Carcinoma. According...
Cadonilimab by Akeso for Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma): Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell...
Cadonilimab by Akeso for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Cadonilimab by Akeso for Squamous Non-Small Cell Lung Carcinoma: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma. According to...
Cadonilimab by Akeso for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
Cadonilimab by Akeso for Epithelial Ovarian Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
Cadonilimab by Akeso for Colorectal Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...
Cadonilimab by Akeso for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Cadonilimab by Akeso for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to...
Cadonilimab by Akeso for Vulvar Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II...
Cadonilimab by Akeso for Rectal Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Rectal Cancer. According to GlobalData, Phase II...
Cadonilimab by Akeso for Metastatic Pancreatic Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase...
Cadonilimab by Akeso for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
Cadonilimab by Akeso for Gastric Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Cadonilimab by Akeso for Non-Small Cell Lung Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Cadonilimab by Akeso for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer). According...
Cadonilimab by Akeso for Small-Cell Lung Cancer: Likelihood of Approval
Cadonilimab is under clinical development by Akeso and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...